Literature DB >> 25016976

The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.

Can Sarisozen1, Abraham H Abouzeid1, Vladimir P Torchilin2.   

Abstract

Multicellular 3D cancer cell culture (spheroids) resemble to in vivo tumors in terms of shape, cell morphology, growth kinetics, gene expression and drug response. However, these characteristics cause very limited drug penetration into deeper parts of the spheroids. In this study, we used multi drug resistant (MDR) ovarian cancer cell spheroid and in vivo tumor models to evaluate the co-delivery of paclitaxel (PCL) and a potent NF-κB inhibitor curcumin (CUR). PCL and CUR were co-loaded into the polyethylene glycol-phosphatidyl ethanolamine (PEG-PE) based polymeric micelles modified with transferrin (TF) as the targeting ligand. Cytotoxicity, cellular association and accumulation into the deeper layers were investigated in the spheroids and compared with the monolayer cell culture. Comparing to non-targeted micelles, flow cytometry and confocal imaging proved significantly deeper and higher micelle penetration into the spheroids with TF-targeting. Both in monolayers and in spheroids, PCL cytotoxicity was significantly increased when co-delivered with CUR in non-targeted micelles or as single agent in TF-targeted micelles, whereas TF-modification of co-loaded micelles did not further enhance the cytotoxicity. In vivo tumor inhibition studies showed good correlation with the 3D cell culture experiments, which suggests the current spheroid model can be used as an intermediate model for the evaluation of co-delivery of anticancer compounds in targeted micelles.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer cell spheroids; Co-delivery; Curcumin; Micelles; Multi drug resistance; Paclitaxel; Transferrin

Mesh:

Substances:

Year:  2014        PMID: 25016976      PMCID: PMC4252620          DOI: 10.1016/j.ejpb.2014.07.001

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  109 in total

Review 1.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

2.  Taking cell-matrix adhesions to the third dimension.

Authors:  E Cukierman; R Pankov; D R Stevens; K M Yamada
Journal:  Science       Date:  2001-11-23       Impact factor: 47.728

3.  Drug resistance conferred by MDR1 expression in spheroids formed by glioblastoma cell lines.

Authors:  A Kolchinsky; I B Roninson
Journal:  Anticancer Res       Date:  1997 Sep-Oct       Impact factor: 2.480

4.  Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew Mike Rauth; Xiao Yu Wu
Journal:  J Control Release       Date:  2006-09-26       Impact factor: 9.776

5.  Diversity of cell-mediated adhesions in breast cancer spheroids.

Authors:  Andrea Ivascu; Manfred Kubbies
Journal:  Int J Oncol       Date:  2007-12       Impact factor: 5.650

Review 6.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

7.  Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier.

Authors:  M Juweid; R Neumann; C Paik; M J Perez-Bacete; J Sato; W van Osdol; J N Weinstein
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

8.  Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies.

Authors:  Raja Venkatasubramanian; Michael A Henson; Neil S Forbes
Journal:  J Theor Biol       Date:  2008-02-21       Impact factor: 2.691

9.  In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer.

Authors:  Dongin Kim; Zhong Gao Gao; Eun Seong Lee; You Han Bae
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

Review 10.  Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge?

Authors:  Juergen Friedrich; Reinhard Ebner; Leoni A Kunz-Schughart
Journal:  Int J Radiat Biol       Date:  2007 Nov-Dec       Impact factor: 2.694

View more
  31 in total

1.  Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.

Authors:  Giuseppina Salzano; Daniel F Costa; Can Sarisozen; Ed Luther; George Mattheolabakis; Pooja P Dhargalkar; Vladimir P Torchilin
Journal:  Small       Date:  2016-07-19       Impact factor: 13.281

2.  Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model.

Authors:  Bhushan S Pattni; Srikar G Nagelli; Bhawani Aryasomayajula; Pranali P Deshpande; Abhijit Kulkarni; William C Hartner; Ganesh Thakur; Alexei Degterev; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

3.  Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.

Authors:  Christopher Poon; Xiaopin Duan; Christina Chan; Wenbo Han; Wenbin Lin
Journal:  Mol Pharm       Date:  2016-10-21       Impact factor: 4.939

4.  Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.

Authors:  Shreya Raghavan; Maria R Ward; Katelyn R Rowley; Rachel M Wold; Shuichi Takayama; Ronald J Buckanovich; Geeta Mehta
Journal:  Gynecol Oncol       Date:  2015-04-22       Impact factor: 5.482

5.  Transferrin-Modified Vitamin-E/Lipid Based Polymeric Micelles for Improved Tumor Targeting and Anticancer Effect of Curcumin.

Authors:  Omkara Swami Muddineti; Preeti Kumari; Balaram Ghosh; Swati Biswas
Journal:  Pharm Res       Date:  2018-03-14       Impact factor: 4.200

6.  Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid.

Authors:  Shravan Kumar Sriraman; Giusseppina Salzano; Can Sarisozen; Vladimir Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2016-06-02       Impact factor: 5.571

Review 7.  Polyphenols delivery by polymeric materials: challenges in cancer treatment.

Authors:  Orazio Vittorio; Manuela Curcio; Monica Cojoc; Gerardo F Goya; Silke Hampel; Francesca Iemma; Anna Dubrovska; Giuseppe Cirillo
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 8.  Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.

Authors:  Shizhu Chen; Keni Yang; Ruslan G Tuguntaev; Anbu Mozhi; Jinchao Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanomedicine       Date:  2015-12-17       Impact factor: 5.307

Review 9.  Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy.

Authors:  Shan-Shan Qi; Jia-Hui Sun; Hao-Han Yu; Shu-Qin Yu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 10.  Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.

Authors:  Shruti Rawal; Mayur Patel
Journal:  Nanomicro Lett       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.